CDC123 missense variants emerge as a new cause of neurodevelopmental disease
Rare variants in CDC123 now have a direct mechanistic link to pediatric disease. In four unrelated families, children with neurodevelopmental delays, hypotonia, and motor dysfunction carried heterozygous missense changes in the gene, and the experimental data point to a biologically coherent defect: impaired assembly of the CDC123-eIF2 complex and downstream suppression of protein synthesis.
This matters because eIF2 sits at the center of translation initiation, the cellular process that converts genetic information into protein. When that machinery falters during brain development, the consequences are expected to surface early and often in the nervous system, where growth, synapse formation, and circuit refinement depend on tightly regulated protein production. The work places CDC123 alongside other translation-related genes that have already been tied to neurodevelopmental phenotypes.
Pediatric phenotypes matched a translation-factor defect
The affected probands shared a recognizable clinical pattern: developmental delay, hypotonia, and motor dysfunction. No claim is made here about a single universal syndrome, but the convergence of those findings across unrelated families supports a shared molecular vulnerability rather than a random assortment of isolated clinical problems. The identified variants were not common polymorphisms; the investigators used allele-frequency appraisal, protein conservation analysis, structural modeling, and functional assays to judge pathogenic potential.
Three novel missense variants were identified among the families. The central question was whether those substitutions merely marked genetic variation or whether they disrupted the normal job of CDC123, an essential chaperone required for eIF2 heterotrimer assembly. The experimental answer landed on the second interpretation.
Structural disruption translated into measurable functional loss
CDC123 helps bring together the eIF2 subunits, and that interaction is not a minor molecular detail. eIF2 is composed of α, β, and γ subunits, and proper assembly is necessary for efficient initiation of protein synthesis. Variants that alter CDC123 behavior can therefore create a bottleneck at the very first step of translation, reducing the cell’s ability to sustain growth and build protein in an orderly way.
The biochemical and cell-based experiments showed that the variants damaged CDC123 activity. They altered CDC123-eIF2 subunit interactions and reduced cell growth. In humanized yeast and human cell-based systems, the mutant proteins did not behave like benign substitutions. Instead, they interfered with normal function in ways consistent with pathogenicity.
One result stands out sharply: the variants did not act simply by lowering gene dosage. They behaved as dominant-negative alleles in yeast, impairing cell growth and protein synthesis rather than causing a straightforward haploinsufficiency state. In practical molecular terms, that means the abnormal protein does not merely leave the cell with less CDC123; it actively interferes with the normal machinery.
Why eIF2 biology fits the neurologic presentation
Translation initiation is one of the most energy-intensive and tightly controlled cellular programs in human biology. Neurons are especially sensitive to disruptions in this pathway because they require sustained, localized protein production for migration, axon guidance, synaptic maturation, and plasticity. A defect in the CDC123-eIF2 axis therefore offers a plausible route from genotype to phenotype: the mutation compromises a chaperone needed for eIF2 assembly, eIF2 function drops, protein synthesis slows, and neurodevelopment suffers.
The study also aligns with prior observations involving eIF2γ variants, which already had been linked to neurodevelopmental impairment. This new work extends that biology upstream, showing that a chaperone required for assembling the eIF2 complex itself can produce a comparable developmental consequence. The pathway is the same, but the point of failure shifts one step earlier in the process.
Human disease now reaches a previously unproven gene
This is the first link between CDC123 missense variants and human disease. That claim rests on multiple layers of evidence, not a single assay. The families supplied the clinical signal, sequence analysis suggested rarity and conservation, structural modeling supported functional relevance, and the cell-based systems confirmed impaired activity. Each layer reinforced the others.
The findings also sharpen how clinicians and laboratories might think about variants of uncertain significance in genes involved in translation. A missense change in a highly conserved residue is not enough on its own to declare pathogenicity, but the combination of patient phenotype, rarity, structural prediction, and direct functional disruption creates a much stronger case. For genetic diagnosis, that difference can move a variant out of the realm of ambiguity and into the category of a credible disease-causing allele.
What this means for interpretation of developmental delay panels
Neurologic genetics panels increasingly identify rare variants in housekeeping genes, and translation factors are a recurring theme in unsolved neurodevelopmental disorders. This preprint adds CDC123 to that list with a mechanistic story that is unusually complete for an early report. It also reinforces a broader principle: core cellular proteins can produce organ-selective disease when the developing brain is the most vulnerable tissue to reduced translational capacity.
The study is still a preprint and has not undergone peer review, so the field will need replication in additional families and deeper clinical annotation before the gene-disease association can be treated as settled. Even so, the biological signal is difficult to dismiss. Defective CDC123 did not merely coexist with developmental symptoms; it altered a fundamental protein-assembly pathway in a direction that fits the observed pediatric phenotype.
Future work will need to determine how widely CDC123-related disease extends, whether specific variant classes produce distinct severity patterns, and how reduced eIF2 assembly influences neuronal development across tissues and developmental stages. For now, the most concrete conclusion is the simplest one: a chaperone once viewed through basic cell biology now sits squarely in the genetics of human neurodevelopment.